COVID-19 in patients with acute leukemia: 3 years' experience of pandemic
Authors:
- T. S. ChudnovaTCT. S. Chudnova
- E. N. MisyurinaEME. N. Misyurina
- E. A. BaryakhEBE. A. Baryakh
- T. N. TolstykhTTT. N. Tolstykh
- L. T. ShimanovskayaLSL. T. Shimanovskaya
- D. E. GagloevaDGD. E. Gagloeva
- E. I. ZhelnovaEZE. I. Zhelnova
- A. B. MakeshovaAMA. B. Makeshova
- K. V. YatskovKYK. V. Yatskov
- E. N. ZotinaEZE. N. Zotina
- D. D. IvanovaDID. D. Ivanova
- M. A. MingalimovMMM. A. Mingalimov
Open Access
- 15 January 2024
- journal article
- review article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (4) , 45-52
Abstract
Patients with acute leukemia are one of the most vulnerable risk groups for infection with SARS-CoV-2 and severe course of coronavirus infection. During the first 2 years of the pandemic, the mortality rate of patients with acute leukemia was 11-48 %, depending on leukemia type, and only reached population levels in 2022. Risk factors for severe COVID-19 in patients with acute leukemia are old age, concomitant cardiac pathology, metabolic syndrome, and the absence of acute leukemia remission. Chemotherapy administered one month before hospitalization with COVID-19 diagnosis showed statistical significance in influencing hospital mortality only in the group of patients with acute myeloid leukemia. Despite this, the international medical community has recommended delaying the start of chemotherapy until clinical symptoms of coronavirus infection have completely resolved and a negative test result for SARS-CoV-2 has been obtained for all types of leukemia. Currently, the most optimal tactic is to prevent SARS-CoV-2 infection by vaccinating patients with acute leukemia receiving antitumor treatment. If the immunological response to vaccination is insufficient, it is possible to use virus-neutralizing monoclonal antibodies as a safe and effective method of primary prevention of COVID-19.Keywords
This publication has 55 references indexed in Scilit:
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- Risk factors and outcome of COVID-19 in patients with hematological malignanciesExperimental Hematology & Oncology, 2020
- Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international expertsThe Lancet Haematology, 2020
- Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL studyBritish Journal of Haematology, 2020
- Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow TransplantationBone Marrow Transplantation, 2020
- Hematological findings in coronavirus disease 2019: indications of progression of diseaseAnnals of Hematology, 2020
- Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow?American Journal of Hematology, 2020
- Targeting potential drivers of COVID-19: Neutrophil extracellular trapsJournal of Experimental Medicine, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020